EP3295943A1 — Aqueous suspension agent comprising glucocorticosteroid nanoparticles
Assigned to Activus Pharma Co Ltd · Expires 2018-03-21 · 8y expired
What this patent protects
[Problem to be Solved] An object is to provide an aqueous suspension containing as an active component a glucocorticosteroid compound. The object specifically is to provide a practically usable pharmaceutical composition containing as the active component a glucocorticoster…
USPTO Abstract
[Problem to be Solved] An object is to provide an aqueous suspension containing as an active component a glucocorticosteroid compound. The object specifically is to provide a practically usable pharmaceutical composition containing as the active component a glucocorticosteroid compound. [Solution] The present invention is to provide an aqueous suspension containing nanoparticles of a glucocorticosteroid compound and a dispersion stabilizer, the aqueous suspension containing the nanoparticles having a mean particle diameter of 300 nm or less and a D90 particle diameter of 450 nm or less, pharmaceutical compositions for parenteral administrations, injections, eye drops or ear drops containing the aqueous suspension, more specifically an eye drop for treating or preventing inflammatory diseases of the eye or an ear drop for treating or preventing inflammatory diseases of the ear.
Drugs covered by this patent
- Temovate (CLOBETASOL PROPIONATE) · Fougera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.